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Abstract
Background: Treatment of shigellosis in rabbits with butyrate reduces clinical severity and counteracts the
downregulation of cathelicidin (CAP-18) in the large intestinal epithelia. Here, we aimed to evaluate whether
butyrate can be used as an adjunct to antibiotics in the treatment of shigellosis in patients.
Methods: A randomized, double-blind, placebo-controlled, parallel-group designed clinical trial was conducted.
Eighty adult patients with shigellosis were randomized to either the Intervention group (butyrate, n = 40) or the
Placebo group (normal saline, n = 40). The Intervention group was given an enema containing sodium butyrate
(80 mM), twice daily for 3 days, while the Placebo group received the same dose of normal saline. The primary
endpoint of the trial was to assess the efficacy of butyrate in improving clinical, endoscopic and histological
features of shigellosis. The secondary endpoint was to study the effect of butyrate on the induction of antimicrobial
peptides in the rectum. Clinical outcomes were assessed and concentrations of antimicrobial peptides (LL-37,
human beta defensin1 [HBD-1] and human beta defensin 3 [HBD-3]) and pro-inflammatory cytokines (interleukin-1β
[IL-1β] and interleukin-8 [IL-8]) were measured in the stool. Sigmoidoscopic and histopathological analyses, and
immunostaining of LL-37 in the rectal mucosa were performed in a subgroup of patients.
Results: Compared with placebo, butyrate therapy led to the early reduction of macrophages, pus cells, IL-8 and IL-1β
in the stool and improvement in rectal histopathology. Butyrate treatment induced LL-37 expression in the rectal
epithelia. Stool concentration of LL-37 remained significantly higher in the Intervention group on days 4 and 7.
Conclusion: Adjunct therapy with butyrate during shigellosis led to early reduction of inflammation and enhanced LL-37
expression in the rectal epithelia with prolonged release of LL-37 in the stool.
Trial Registration: ClinicalTrials.gov, NCT00800930.
Keywords: Short chain fatty acids, Butyrate, Shigellosis, Innate immunity, Antimicrobial peptides, Cathelicidin, LL-37,
Inflammation, Pro-inflammatory cytokines, Rectal mucosa
Background
Shigellosis continues to be a major health burden with
an annual incidence rate of 125 million cases in Asia, al-
though the fatality rate has decreased substantially over
the last two decades [1]. Invasion of the colonic mucosa
by Shigella leads to inflammation-mediated destruction
of the mucosal barrier. The resultant manifestations are
the passage of bloody mucoid loose stools, abdominal
cramps, rectal tenesmus and fever [2]. The management
of shigellosis depends on antibiotics, but the emergence
of antibiotic-resistant strains is limiting their effective-
ness. Moreover, it is often the case that antibiotic treat-
ment cannot resolve the chronic inflammatory response
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of shigellosis [3,4]. Furthermore, the use of antibiotics
can have systemic side-effects and disturb the balance of
normal flora, exacerbating the disease or making the
host prone to other opportunistic pathogens [5]. There-
fore, new drugs need to be developed that may act alone
or as adjunct to antibiotic therapy.
Antimicrobial peptides (AMPs) are front-line compo-
nents of innate immunity in multicellular organisms [6].
These peptides constitute an antimicrobial arsenal
against a wide range of pathogens at the host-microbe
interfaces. Our group and others have previously shown
that Shigella spp downregulates the expression of human
cathelicidin LL-37 and beta defensins in colonic epithe-
lial cells, one of several mechanisms employed by this
pathogen to evade host defenses [7,8].
Short chain fatty acids (SCFAs), primarily acetate, propi-
onate and butyrate are bacterial fermentation products of
undigested dietary carbohydrates in the colon. SCFAs,
principally butyrate, supply energy and exert various
effects on colonocytes, influencing colonic health [9]. Rab-
bani et al. first demonstrated that a mixture of SCFAs can
improve the clinicopathologic and bacteriologic features
of experimental shigellosis in rabbits [10]. Later, we
showed that oral butyrate treatment of rabbits leads to
clinical recovery and reduced Shigella count in the stool
[11]. In addition, Shigella-mediated downregulation of
cathelicidin CAP-18 in the large intestinal epithelia of rab-
bits was counteracted by butyrate treatment [11]. In a ran-
domized clinical trial, ingestion of green banana, which
induces luminal SCFA production, reduced clinical sever-
ity of childhood shigellosis [12]. However, to our know-
ledge, no study has been carried out to evaluate the
efficacy of butyrate therapy on recovery following shigello-
sis in humans. Therefore, in this study, we aimed to assess
the potential of butyrate as an adjunct to antibiotic
therapy in adult shigellosis in terms of clinical, endo-
scopic and histopathological recovery. The effect of
butyrate on the expression of antimicrobial peptides
and pro-inflammatory cytokines was also investigated.
Methods
This study is reported according to CONSORT (Consoli-
dated Standards of Reporting Trials) guidelines.
Study design
A double-blind, placebo-controlled, parallel-group
designed, equally randomized (1:1) clinical trial was con-
ducted in Bangladesh from January 2005 to January 2009.
The Trial Registration number is ClinicalTrials.gov,
NCT00800930.
Ethics statement
The trial was conducted in accordance with the declar-
ation of Helsinki. The study protocol was approved by the
Ethical Review Committee of the International Centre for
Diarrheal Disease Research, Bangladesh (icddr,b) and by
the Directorate General of Drug Administration (DGDA)
of the Government of the People’s Republic of Bangladesh.
Written informed consent was obtained from all eligible
participants before participation.
Intervention compound
Sodium butyrate was purchased from Merck Schuchardt
OHG, Hohenbrun, Germany and the analysis for
pharmaceutical grade was performed by Apoteket Pro-
duction Laboratory, Stockholm, Sweden.
Selection of patients, study settings and locations
Adult (18–55 years) patients of both sexes having occult
blood and mucus in their stool and with a history of 0–
4 days of diarrhea were selected as presumptive cases of
shigellosis in the outpatient clinic of the Dhaka Hospital
and the Matlab Hospital of icddr,b. The Dhaka Hospital
serves the metropolitan district of Dhaka and its sur-
rounding areas, while the Matlab Hospital provides
health care in a rural setting.
Clinical management
Following selection, standard clinical history was taken
and physical examinations were performed. All patients
were given pivmecillinam (400 mg, every 8 hours for
5 days) as empirical therapy. If required, oral or intraven-
ous rehydration was given to patients during
hospitalization. The patients were kept in the study ward
for 4 days to administer enema and were released on the
5th day. If the diarrhea did not subside by 5th day, they
were kept in the study ward for additional days until diar-
rhea resolved. Standard treatment was maintained, even if
the patients were no longer in the study. All patients
received the usual hospital food three times a day.
Inclusion and exclusion criteria for enrollment
Patients aged 18–55 years with 0–4 days duration of
diarrhea and with culture-confirmed Shigella spp (all
Shigella spp.) in their stool were eligible for the study, if
they did not meet any exclusion criteria. The exclusion
criteria were: (1) treatment with antimicrobial agents be-
fore attending the icddr,b hospital; and (2) presence of
clinical symptoms of other concomitant infections such
as chronic respiratory infections, other concomitant
gastrointestinal infections.
Outcome measures
The primary endpoint of the trial was to assess the effi-
cacy of sodium butyrate enema in improving clinical,
endoscopic and histological features of shigellosis.
Clinical scoring was set to evaluate the clinical status
(given below). Reduction in clinical scores indicated
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improvement. The levels of pro-inflammatory cytokines,
interleukin-8 (IL-8) and interleukin-1β (IL-1β) were
assessed in the stool of all patients to support endo-
scopic and histopathological features of rectal inflamma-
tion, which were analyzed in a subgroup of patients.
The secondary endpoint was the induction of en-
dogenous AMPs in the rectum through butyrate treat-
ment. The release of LL-37, human beta defensin 1
(HBD-1) and human beta defensin 3 (HBD-3) in the
stool, and the expression of LL-37 in the rectal mucosa
were evaluated.
Sample size calculation
Sample size estimation was based on the assumption of
a 30% clinical improvement in the Intervention group
over the Placebo group at a 5% significance level with
80% statistical power. The estimated sample size was 38
in each group. Accounting for 5% loss to follow-up or
dropouts, the sample size was finalized at 40 cases per
group.
Randomization, allocation concealing, blinding,
implementation and intervention
Patients were randomized with a 1:1 allocation ratio using
a simple randomization procedure (computer generated
list of random numbers prepared by an independent per-
son not involved in the study) to either the Intervention
group (butyrate, n = 40) or the Placebo group (normal sa-
line, n = 40). An independent pharmacist dispensed either
sodium butyrate or placebo into bottles and consecutively
numbered the bottles for each patient according to the
randomization list. Enrollment of patients to the study
ward was carried out by the nursing staff on duty. The as-
signment of patients to the Intervention or Placebo group
was concealed to both the investigators and patients by
enclosing the assignment card that contained the code
number for each patient in a sealed envelope. The enve-
lope was opened only at the time of allocating patients to
the study by the responsible physician. After enrollment,
the Intervention group received 80 mM sodium butyrate
isotonic enema, every 12 hours for 72 hours. Sodium bu-
tyrate was dissolved in water and osmolarity of the enema
solution was adjusted to 295 mOsm/L with sterile non-
pyrogenic normal saline. The Placebo group received the
same dose of normal saline enema (308 mOsm/L). The
enema solution was administered over 7–8 minutes after
which the patients were kept in a supine position for an-
other 60 minutes. If the patients could not retain the
enema for 30 minutes due to defecation, they were given a
2nd dose of enema.
Clinical investigations and follow-up visits
Patients were observed for clinical outcomes for 4 con-
secutive days starting from the enrollment day (day 1).
Each clinical parameter was given grading scores: dur-
ation of diarrhea: 1 = 1-2 days, 2 = 3 days, 3 = 4 days;
stool frequency: 1 = 1-3 times, 2 = 4-7 times, 3 ≥8 times;
stool output (g): 1 = 0-76, 2 = 77-190, 3 = 191-382, 4
≥383; stool consistency: 1 = formed, 2 = soft, 3 =watery;
body temperature (°C): 1 = 36.1-37.4, 2 ≥37.5; for vomit-
ing, tenesmus, dehydration, abdominal pain, anorexia
and mucus in stool: 1 = absent, 2 = present. Scores for
each parameter were combined to set an overall clinical
score. Frequency of red blood cells (RBC), pus cells and
macrophages in the stool was observed by routine
microscopic examinations (RME). The grading for RBC
was: 1 = 0, 2 = 1-10, 3 = 11-20, 4 = 21-50 and 5 >50; for
pus cells: 1 = 0-10, 2 = 11-20, 3 = 21-50 and 4 >50; for
macrophages: 1 = 0, 2 = 1-5, 3 = 6-10 and 4> 10. If diar-
rhea subsided, patients were released from the hospital
on 5th day and asked to return for a follow up visit on
day 7.
Sigmoidoscopic (Olympus Tokyo, Japan) examination
was performed in patients, enrolled only in Dhaka Hos-
pital (Intervention group, n = 15 and Placebo group,
n = 11) on day 1 and day 7 to monitor inflammation in
the rectal mucosa. Inflammation was graded as mild,
moderate or severe based on the modified Baron score
[13]. One patient in the Placebo group declined to
undergo sigmoidoscopic examination on day 7. However,
follow-up stools were collected from that patient. There-
fore, that patient was excluded from the sigmoidoscopic
and subsequent histologic and immunohistochemical
analyses. Due to lack of endoscopic facilities in the
Matlab Hospital, patients in Matlab (n = 49) did not
undergo sigmoidoscopic examination. The patients who
underwent sigmoidoscopy are referred hereafter as a
subgroup.
Specimen collection and processing
Stool specimens were collected from each patient on the
day of enrollment (day 1), on each of the following 3 days
and on day 7. Stool samples were diluted 10-fold with
60% acetonitrile in 1% aqueous trifluoroacetic acid
(TFA) and extracted overnight at 4°C. The extracts
were centrifuged and supernatants were passed
through a 0.45 μm filter, aliqouted, lyophilized and
stored at −20°C.
Rectal biopsy samples, 10 to 12 cm from the anus,
were collected from patients enrolled in the Dhaka Hos-
pital on days 1 and 7. At each time point, 3 biopsy sam-
ples were obtained, fixed in buffered formalin,
embedded in paraffin and cut into 3 μm thick sections
by a microtome (RM 2055, Leica, Heidelberg, Germany).
The sections were mounted on vectabond-coated glass
slides (Superfrost/plus, Menzel-Glaser, Germany), dried
overnight at 37°C and kept at room temperature.
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Blood was collected on days 1 and 4 for toxicity
assessments.
Bacterial count in stool
Bacterial load in the stool was quantified by plating ser-
ial dilutions of stool onto MacConkey agar plates with
colonies being counted following overnight incubation at
37°C. The results were expressed as colony forming
units (CFU) per gram of stool.
Enzyme linked immunosorbent assay (ELISA)
LL-37, HBD-1, HBD-3, IL-8 and IL-1β were measured
in stool extracts by sandwich ELISA. Lyophilized stool
extracts were dissolved in Tris-buffer saline (TBS) for
LL-37 or in appropriate dilution buffer as recommended
by the manufacturer for HBD-1, HBD-3 (Alpha diagnos-
tic, Texas, USA), IL-8 and IL-1β (BD Biosciences Phar-
mingen, California, USA).
For LL-37 concentration, an in-house method was
used. Microtiter plates (96-well, black; Nunc, Roskidle,
Denmark) were coated with monoclonal anti-LL-37
(produced in our laboratory). After blocking nonspecific
sites, standards (synthetic LL-37 peptide [Innovagen AB,
Lund, Sweden]) and stool samples were added in dupli-
cate and incubated overnight at 4°C. Plates were then
incubated with biotinylated polyclonal LL-37 (Innovagen
AB) and streptavidin-alkaline phosphatase (Millipore,
California, USA) for 2 hours each at room temperature.
Finally, substrate 4-methylumbelliferyl phosphate (4-
MUP) (Invitrogen, Leiden, The Netherlands) was added
to produce a fluorescent end product. The fluorescent
intensity was measured by Infinite 200 spectrophotom-
eter (Tecan, Männedorf, Switzerland) at an excitation
wavelength of 360 nm and an emission wavelength of
450 nm. The LL-37 concentration in stool extracts was
then extrapolated from the standard curve.
ELISA for HBD-1, HBD-3, IL-8 and IL-1β was carried
out according to manufacturer’s instructions.
Histology and immunohistochemistry
Paraffin embedded rectal biopsy sections were deparaffi-
nized, stained with hematoxylin and eosin and examined
by a pathologist. Histological grading of inflammation as
mild, moderate or severe was done according to the cri-
teria described earlier [14].
For immunohistochemical detection of LL-37, deparaf-
finized sections were microwave-treated in retrieval buf-
fer (Dako, Glostrup, Denmark) and endogenous
peroxidase activity was quenched by hydrogen per-oxide
(H2O2). The sections were then incubated overnight with
rabbit polyclonal LL-37 antibody (3 μg/ml) (Innovagen
AB), followed by sequential incubation with biotinylated
goat anti-rabbit IgG (Dako) and avidin-biotin horserad-
ish peroxidase complex (Dako), each for 1 hour. The
color reaction (brown) was developed by adding diami-
nobenzidine (Dako) as the substrate for peroxidase en-
zyme. To control for specific staining, synthetic LL-37
peptide was incubated overnight at 4°C at a 20-fold
higher concentration with the LL-37 antibody, and the
mixture was used for immunostaining.
Image analyses
In situ immunohistochemical staining of LL-37 was ana-
lyzed by the image analysis system Quantimate Q550
(Leica, Wetzlar, Germany) according to Cunnane G
et al. [15]. The epithelial and non-epithelial areas of rec-
tal mucosa were separately assessed for the quantifica-
tion of LL-37 staining in each tissue section at 400x
magnification and the results were given as ACIA
(Acquired Computerized Image Analysis) score. Since
there were erosions of surface epithelium (SE) at mul-
tiple locations, ACIA scores of LL-37 in SE were
expressed in terms of ACIA score per unit SE length.
Biosafety evaluation of treatment
For biosafety evaluation, the serum levels of biomarkers for
kidney (urea and creatinine) or liver (alanine transaminase
and γ-glutamyl transferase) toxicity were assessed.
Statistical analyses
Statistical analyses were performed using the statistical
software packages SigmaStat (version 3.1; Systat Soft-
ware Inc., Point Richmond, CA, USA) and SPSS for
Windows (release 17; SPSS Inc, Chicago, Illinois, USA).
Data were expressed as number of patients, n (% of
patients) for categorical variables, and as mean with
standard deviation or median with 25–75 percentiles for
quantitative variables. Changes of categorical variables
over time in two groups were compared using Chi-
square test. Quantitative data were transformed (e.g. nat-
ural log or log) when not normally distributed, and ana-
lyses were performed on the transformed variables.
Two-way repeated measures ANOVA was performed to
determine significant interaction between butyrate and
placebo therapy on different days, and when interaction
was significant, the Holm-Sidak post-hoc comparison
procedure was used to compare the effects of butyrate
therapy on outcome measures. The overall significance
level was set at P< 0.05.
Effect sizes (ES) of butyrate and placebo adjunct ther-
apy were estimated. ES can be interpreted in terms of
the average percentile standing of the average experi-
mental (Intervention) group relative to the average con-
trol (Placebo) group or in terms of the percent of non-
overlap of the Intervention group's scores with those of
the Placebo group. An ES of 0.0 to 0.2 indicates that the
mean of the Intervention group is between 50 and 58
percentiles of the Placebo group, and the score
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distribution for the Intervention group overlaps almost
completely with the score distribution for the Placebo
group with 0% to 14.7% of non-overlap (small). An ES
between 0.6 and 0.8 indicates that the mean of the Inter-
vention group is between 73 and 79 percentiles (large)
with 38.2% to 47.4% of non-overlap, respectively.
Patients with shigellosis assessed 
for eligibility (n=94)
Excluded (n=14):
Declined to participate (n=2)
Lacking inclusion criteria (n=7)
Meeting exclusion criteria (n=5)
Randomized (n=80)










































































Figure 1 Flow diagram for enrollment, allocation, follow-up and analysis of study patients according to CONSORT.




Figure 1 shows the flow of patients from screening, en-
rollment, allocation to follow-up and analysis. Forty two
male and 34 female patients with a mean age of
34.5 years and average body weight of 45.4 kg were ana-
lyzed in the study from January 2005 to January 2009.
There were no significant differences in the baseline
characteristics and the clinical features between butyrate
and placebo treated patients (Table 1).
Effect of butyrate treatment on clinical and
microbiological outcomes in shigellosis
There were no significant differences in the clinical re-
covery between the Intervention and Placebo groups of
patients in terms of disease scores (p = 0.73) (Data not
shown). However, routine microscopic examination of
stool samples revealed significant reduction in pus cells
(p = 0.009) and macrophages (p = 0.043) by day 2 in the
Intervention group compared with the Placebo group
(Table 2). Since all patients received antibiotic treatment,
Shigella bacterial count in the stool samples disappeared
within 48 hours in all patients (data not shown) and
hence, the effects of butyrate therapy on bacterial counts
could not be evaluated.
Butyrate treatment reduces inflammation of rectal
mucosa in shigellosis
Sigmoidoscopic examination showed that all 15 patients
in the Intervention group had inflammation in the rectal
mucosa, either mild (n = 7), moderate (n = 5) or severe
(n = 3) on day 1. In the Placebo group, all 11 patients
had either mild (n = 6), moderate (n = 4) or severe (n = 1)
inflammation on day 1. Rectal inflammation was healed/
reduced on day 7 in 11 patients (73.3%) in the Interven-
tion group in contrast to 6 patients (54.5%) in the Pla-
cebo group (Table 3). Notably, in the Intervention
group, inflammation was completely healed in 9 patients
(60%) by day 7, who had presented either severe (n = 3),
moderate (n = 2) or mild (n = 4) inflammation on day 1
(Table 3). In the Placebo group, 4 patients (36%) includ-
ing 1 with moderate and 3 with mild inflammation on
day 1 showed no inflammation by day 7 (Table 3).
Histological analysis revealed that 14 patients in the
Intervention group had inflammation in the rectal mucosa
on day 1; either mild (n= 7), moderate (n= 4) or severe
(n= 3) (Figure 2). Ten patients in the Placebo group had
either mild (n= 5), moderate (n= 3) or severe (n= 2) in-
flammation. One patient in each group had no inflamma-
tion on day 1 and was thus excluded from analysis. On
day 7, 13 patients (92.8%) in the Intervention group had
improved histological features (Figure 2) of inflammation
in contrast to 5 patients (50%) in the Placebo group
(Table 3). The number of patients with improved histology
on day 7 was significantly higher in the Intervention group
Table 1 Demographic data of Shigella-infected patients
on the day of enrollmenta






Age, yrs 34.72 ± 13.80 34.97 ± 11.20 0.93
Sex, Male: Female 23:16 19:18 0.66
Body weight, kg 46.04 ± 6.08 45.03 ± 6.96 0.5
Duration of diarrhea, days 3.41 ± 1.46 3.21 ± 0.71 0.97
Frequency of
defecation, times/d
4.41 ± 4 5.06 ± 4 0.32
Stool output, g 124.71 ±148.35 83.42 ± 77.69 0.21
Fever, n (%) 18 (46.1%) 16 (43.2%) 0.82
Tenesmus, n (%) 25 (64.1%) 26 (70.3%) 0.63
Abdominal cramping, n (%) 32 (82%) 31 (83.8%) 1.0
Blood in stool, n (%) 17 (43.6%) 17 (45.9%) 1.0
aData are given as mean ± standard deviation, proportion of patients or
number of patients (% of total patients in each group).
bStudent-t test or Chi-square test was used to compare between the groups
for quantitative or categorical data, respectively. Significance: p≤ 0.05.
Table 2 Comparison of stool microscopic outcomes between Intervention and Placebo groups of patients with
shigellosisa
No. of patient improved n (%) compared to day 1 Odds ratiob
(95% CI)
p
valuebMicroscopic features in stool Intervention groupn=39 Placebo groupn=37
RBC at day-2 29 (74.4) 22 (59.5) 1.85 (0.7-4.9) 0.22
RBC at day-3 32 (82)) 31 (83.8) 0.88 (0.3-2.9) 1.0
Pus cell at day-2 30 (76.9) 17 (45.9) 3.72 (1.4-10) 0.009
Pus cell at day-3 32 (82) 30 (81.1) 1.1 (0.3-3.4) 1.0
Macrophage at day-2 32 (82) 22 (59.5) 3.12 (1.1-8.9) 0.043
Macrophage at day-3 38 (97.4) 34 (91.9) 3.3 (0.3-33.8) 0.35
Abbreviations: RBC Red blood cell, CI Confidence interval.
aData are given as number of patients (% of total patients in each group).
bChi-square test was used to compare between the groups. Significance: p≤ 0.05.
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than that in the Placebo group (p= 0.035) (Table 3). In the
Intervention group, histology was normal (Figure 2) by
day 7 in 11 patients (78.6%) (1 patient with severe, 3
patients with moderate and 7 patients with mild inflam-
mation on day 1) (Table 3). In the Placebo group, only 1
patient (10%) had completely healed rectal mucosa on day
7, which was significantly lower compared with the Inter-
vention group (p= 0.005) (Table 3). Notably, 1 patient with
moderate inflammation on day 1 got worse with severe
histology on day 7 in the Placebo group. These data sug-
gested the contribution of butyrate treatment in the re-
duction of rectal inflammation.
Effect of butyrate treatment on release of pro-
inflammatory cytokines in stool
Concentration of IL-8 in the stool declined significantly
over time (from day 1 to days 4 and 7) (p≤ 0.001) in both
Placebo and Intervention groups. However, the decline in
the Intervention group was significantly higher compared
with that found in the Placebo group (p= 0.048)
(Figure 3A). Similarly, IL-1β level in the stool reduced in
both groups over time, and the reduction was higher in
the Intervention group compared with the Placebo group,
although the difference was not significant (p= 0.078)
(Figure 3B). In terms of the decrease of IL-8 level in the
stool on day 4, the effect size was 0.18 (small) for the
Intervention group compared with the Placebo group.
Effect of butyrate treatment on LL-37 expression in rectal
mucosa
There was a significant increase in the expression of LL-
37 in the surface epithelium (SE) of the rectum from day 1
to day 7 in the Intervention group compared with the Pla-
cebo group (p= 0.04) (Figures 2 and 4). No significant




Number of patients improved n (%)






Number of patients healed n (%)






Intervention group Placebo group Intervention group Placebo group
By sigmoidoscopy 11 (73.3) 6 (54.5) 2.29 0.324 9 (60) 4 (36) 2.63 0.239
n = 15 n= 11 (0.4-11.9) n = 15 n= 11 (0.5-13.1)
By histology 13 (92.8) 5 (50) 13 0.035 11 (78.6) 1(10) 33 0.005
n = 14c n = 10c (1.2-140.7) n = 14c n = 10c (2.9-374.3)
Abbreviation: CI Confidence interval.
aData are given as number of patients (% of total patients in each group).
bChi-square test was used to compare between groups. Significance: p≤ 0.05.
cOne patient in the Intervention and one in the Placebo group did not have histological feature of inflammation on day 1 and thus excluded from the analysis.
Figure 2 Rectal tissues from adult patients with shigellosis representing histology (A-C) and LL-37 immunostaining (D-F). (A) SE was
completely eroded at the onset of disease (arrow heads). Huge appearance of blood (deep pink) due to hemorrhage was also evident in LP. (B)
Partial recovery (arrow) of epithelial erosion (arrow head) and hemorrhage on day 7 following placebo treatments. (C) The epithelial erosion
(arrows) and hemorrhage were completely healed by day 7 after treatment with butyrate. (D) Low expression of LL-37 in the SE (arrow heads) on
day 1. (E) LL-37 expression in SE was still low (arrow heads) on day 7 after placebo treatment. (F) Treatment with butyrate led to higher and
intense expression of LL-37 in SE (arrow heads) on day 7. SE: surface epithelium; LP: lamina propria. In figures A, B, C and F, bars equal to 100 μm.
In figures D and E, bars equal to 50 μm.
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changes over time were observed between the two groups
in the expression of LL-37 in the lamina propria (LP)
(p= 0.14) (Figure 4). The effect size for increased epithelial
LL-37 expression on day 7 was small (0.21) for the Inter-
vention group compared with the Placebo group.
Effect of butyrate treatment on release of antimicrobial
peptides in stool
A significant decrease in LL-37 level in the stool from
day 1 to days 4 and 7 was observed (p <0.001) for both
Placebo and Intervention groups. However, LL-37
concentration on day 4 and day 7 in the Intervention
group remained significantly higher than those in the
Placebo group (p <0.001) (Figure 5). There was no sig-
nificant difference between the two groups in terms of
the levels of HBD-1 and HBD-3 throughout the study
period (data not shown). For elevated concentration of
LL-37 in the stool on days 4 and 7, the effect size was
0.96 (large) and 1.53 (large), respectively for the Inter-
vention group compared with the Placebo group.
Biosafety of topical butyrate treatment
The serum levels of urea, alanine transaminase and γ-
glutamyl transferase were within the normal range in
both Intervention and Placebo groups of patients
(Table 4). The levels of creatinine was slightly below the
normal range. However, there was no difference in the
creatinine levels between the Intervention and the Pla-
cebo groups of patients (Table 4).
Figure 3 Levels of Pro-inflammatory cytokines in the stool of
Shigella-infected patients, treated with butyrate or placebo.
Stool specimens were collected on indicated time points from
Intervention (n = 39) and Placebo (n = 37) groups of patients.
Concentrations of (A) IL-8 and (B) IL-1β in stool extracts were
measured by enzyme linked immunosorbent assay (ELISA). Data are
represented as mean± SEM. Two-way repeated measure ANOVA was
performed to determine significant interaction between butyrate
and placebo therapy on different days, and when interaction was
significant the Holm-Sidak post hoc comparison procedure was used
to compare the effects of butyrate therapy on outcome measures.
Significance: p≤ 0.05. Levels of IL-8 and IL-1β diminished
significantly from day 1 to days 4 and 7 (≤ 0.001) in both groups.
Diminution of IL-8 in the Intervention group was significantly higher
than the Placebo group (p = 0.048). Attenuation of IL-1β in the
Intervention group was higher but not significant compared with
the Placebo group (p = 0.078). IL-8: interleukin-8; IL-1β: interleukin-1β.
Figure 4 LL-37 expression in the rectal mucosa of Intervention
or Placebo groups of patients with shigellosis. Rectal biopsies
were obtained on day 1 and day 7 from a subgroup of Shigella-
infected patients, treated with butyrate (n = 15) or placebo (n = 11).
Immunohistochemical detection of LL-37 was performed in paraffin
sections. SE and LP were separately assessed for the quantification
of LL-37 staining in each tissue section and the results were given as
ACIA (Acquired Computerized Image Analysis) score. Lower and
upper boundaries of the boxes and the horizontal bars in between
indicate 25th percentile, 75th percentile and group median
respectively. Single lines extending from the boxes represent lower
and upper quartiles. Each circle above or below the boxes indicates
one outlier. Two-way repeated measure ANOVA was performed to
determine significant interaction between butyrate and placebo
therapy on different days, and when interaction was significant the
Holm-Sidak post hoc comparison procedure was used to compare
the effects of butyrate therapy on outcome measures. Significance:
p≤ 0.05. Expression of LL-37 in SE increased significantly from day 1
to day 7 in the Intervention group compared with the Placebo
group (p = 0.04). There was no significant changes over time
between groups in the expression of LL-37 in LP (p = 0.14). SE-
surface epithelium; LP-lamina propria.
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Discussion
The results of this study show that adjunct therapy with
sodium butyrate enema leads to an early decline in fre-
quency of inflammatory cells and concentrations of pro-
inflammatory cytokines in the stool, but has no obvious
effect on clinical recovery from shigellosis. In a subgroup
of Shigella-infected patients, butyrate treatment resulted
in early improvement of rectal inflammation compared
with placebo-treated patients. Furthermore, the expres-
sion of cathelicidin LL-37 in the rectal epithelium was
significantly enhanced following butyrate treatment.
In our earlier study in a rabbit model of shigellosis,
butyrate treatment resulted in a marked improvement in
clinical outcomes and early reduction of Shigella count
in the stool [11]. We did not observe similar effects in
this study. It is worth mentioning that while rabbits were
given butyrate treatment without any antibiotics,
patients were given butyrate in addition to antibiotics.
Therefore, it is not unexpected that the clinical features
and Shigella count in the stool subsided in all study
patients simultaneously.
The potential anti-inflammatory effects of butyrate
have long been documented. Preventive and therapeutic
effects of butyrate on inflammation were evaluated in
animal models of colitis [16-18]. In patients with ulcera-
tive colitis (UC) or Crohn’s disease (CD), oral/topical ad-
ministration of butyrate (or SCFA mixture), or
stimulation of luminal butyrate production by feeding
dietary fibers, have been shown to reduce clinical and in-
flammatory index in several studies (reviewed in
[19,20]). In experimental shigellosis in rabbits, the in-
flammatory parameters were also reduced with colonic
infusion of an SCFA mixture [10], or by oral administra-
tion of butyrate [11]. No adverse effects of butyrate
treatment were reported in these studies. Here, we have
shown that local luminal administration of butyrate can
significantly improve the histological features of inflam-
mation in the rectum in a subgroup of patients. Butyrate
treatment also resulted in an early decline in pus cells,
macrophages and pro-inflammatory cytokines in the
stool. Hence, butyrate treatment can resolve the persist-
ence of inflammation, which often occurs after clinical
recovery from shigellosis following antibiotic treatment
[3,21]. Furthermore, patients did not exhibit untoward
effects of butyrate treatment as assessed by the levels of
renal and hepatic biomarkers.
The anti-inflammatory effect of butyrate is mediated
primarily through the inhibition of nuclear factor κB
(NF-κB) activation in the large intestinal mucosa [22-
24]. Dysregulated activation of NF-κB in animal models
of colitis, and in patients with UC or CD, was reported
to be inhibited by butyrate, which correlated with
decreased inflammation [25,26]. The anti-inflammatory
activity of butyrate might also be due to the activation of
peroxisome proliferator-activated receptor-γ (PPARγ), a
ligand-activated transcription factor in colonic epithelial
cells [27,28], and the inhibition of interferon-γ signaling
Figure 5 LL-37 level in the stool of Shigella-infected patients,
treated with butyrate or placebo. Stool specimens were collected
on indicated time points from Intervention (n = 39) or Placebo
(n = 37) groups of patients. Level of LL-37 in stool extracts was
measured by enzyme linked immunosorbent assay (ELISA). Data are
represented as mean± SEM. Two-way repeated measure ANOVA was
performed to determine significant interaction between butyrate
and placebo therapy on different days, and when interaction was
significant the Holm-Sidak post hoc comparison procedure was used
to compare the effects of butyrate therapy on outcome measures.
Significance: p≤ 0.05. Concentration of LL-37 decreased significantly
from day 1 to days 4 and 7 (< 0.001) in both groups. The decrease
was significantly higher in the Placebo group than that in the
Intervention group (p <0.001).
Table 4 Levels of hepatic and renal biomarkers in serum of Shigella-infected patients at different timea
Patient
groups
Day Renal biomarkers Hepatic Biomarkers
Creatinine (mg/dL)b Urea (mg/dL)b ALT (U/L)b γ-GT (U/L)b
Intervention 1 0.51 ± 0.04 21.3 ± 3 15.5 ± 1.6 11.4 ± 0.8
4 0.43 ± 0.02 18 ± 1.1 21.9 ± 2.3 11 ± 0.6
Placebo 1 0.49 ± 0.03 18.7 ± 2.6 18.6 ± 2.2 13.4 ± 2.7
4 0.40 ± 0.02 17.3 ± 1.5 21.1 ± 2.4 18.9 ± 4
Abbreviation: ALT Alanine transaminase, γ−GT Gamma glutamyl transferase.
aData are given as mean ± standard error of mean.
bNormal reference values of creatinine: 0.6-1.2 mg/dL (men) and 0.5-1.1 mg/dL (women); urea: 6-24 mg/dL; ALT: 0.01-41U/L (men) and 0.01-31.0U/L (women)
and γ−GT 9-40U/L (men) and 0-35U/L (women).
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[29]. Moreover, involvement of the G-protein coupled
receptor (GPCR) in the anti-inflammatory effect of
SCFA has been demonstrated recently in animal models
of colitis, arthritis and asthma [30].
Treatment with butyrate showed increased expression
of LL-37 in the rectal epithelia compared with placebo
treatment, although there was a general increase in its ex-
pression in both groups after one week. This was in ac-
cordance with our previous finding in experimental
shigellosis, where butyrate treatment counteracted the
downregulation of rabbit cathelicidin in the rectal epithelia
[11]. However, the effect size in patients was small, which
could be due to the fact that butyrate was given as an
enema in patients in contrast to oral therapy in the rabbit
model. Patients may not have completely retained the bu-
tyrate after infusion because of repeated defecation, which
would affect the absorption of butyrate in serum. Recently,
we have shown that the systemic dissemination of butyrate
is necessary to induce cathelicidin expression in epithelial
cells [31]. In parallel to epithelial expression, the release of
LL-37 peptide in the stool also remained significantly
higher on days 4 and 7 in the Intervention group. Since
there was significant reduction of inflammatory cells in
stool from the Intervention group, the prolonged secretion
of LL-37 in the stool may have originated from the healed
epithelium of the large intestine and may play a role in
bactericidal activities.
The current study has a number of limitations. Since
both groups of patients were given antibiotics, it was not
possible to evaluate whether butyrate treatment enhanced
shigellacidal activity in the stool. Butyrate was given as an
enema instead of oral therapy as in rabbits since the bad
smell of butyrate makes it unsuitable for oral therapy in
humans. Repeated use of enemas is troublesome, espe-
cially with regards to patient compliance and the need for
hospital facilities. Oral administration of enteric coated
tablets containing butyrate can be a better alternative,
which was proved to be effective previously in patients
with ulcerative colitis [32]. Induction of luminal butyrate
via ingestion of fermentable fiber supplementation, which
has been successfully used in clinical trials for ulcerative
colitis (reviewed in [20]) and childhood shigellosis [12],
may also be suitable for healing inflammation in shigello-
sis. In addition, consumption of probiotics has recently
been suggested as an interesting approach to reduce intes-
tinal inflammation through the upregulation of luminal
levels of butyrate and butyrate-producing commensal bac-
teria, and the lowering of cecal pH [33]. In fact, these and
additional metabolic shifts in T-bet−/−Rag2−/− mice were
shown to improve colitis scores by creating an unfavorable
environment for the colitogenic Enterobacteriaceae. How-
ever, whether these therapies would also be suitable for
the induction of antimicrobial peptides in the epithelium
remains to be seen.
Conclusion
The current study demonstrates that adjunct therapy with
butyrate enema during shigellosis promotes healing of the
rectal mucosa and reduces luminal content of inflamma-
tory cells and pro-inflammatory cytokines. Butyrate treat-
ment also resulted in enhanced expression of LL-37 in the
rectal epithelia and prolonged secretion of LL-37 in the
stool. However, efficacy of butyrate in clinical recovery
from shigellosis was not evident. Recently, we have shown
that sodium 4-phenylbutyrate (PB), a derivative of butyrate
without the foul smell, provides similar treatment efficacy
as butyrate when given orally to rabbits with experimental
shigellosis [31]. Since PB is already an approved drug for
treating urea cycle disorder, it holds much promise as a
therapeutic alternative for human shigellosis.
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